Evidence map›Paper›PMID 29190707›Full record

Trial reportPloS one2017

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).

David Pasquier, Philippe Nickers, Didier Peiffert, Philippe Maingon, Pascal Pommier, Thomas Lacornerie, Geoffrey Martinage, Emmanuelle Tresch, Eric Lartigau

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01596816 (Intermediate-risk Prostate Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01596816 phase2completednot on this map

Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study

TypeinterventionalSponsorCentre Oscar LambretRan2010 to 2018Enrolled76ConditionsCancerArmsFirst part of treatment : Conformal irradiation, Fiducials placement, Second part : hypofractionated stereotactic boost
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

David PasquierCentre Oscar Lambret, Academic Department of Radiation Oncology, University Lille II, Lille, France.ORCID http://orcid.org/0000-0001-6019-7309
Philippe NickersCentre Oscar Lambret, Academic Department of Radiation Oncology, University Lille II, Lille, France.
Didier PeiffertInstitut de Cancérologie de Lorraine-Alexis Vautrin, Nancy, France.
Philippe MaingonLa Pitié Salpêtrière Charles Foix, UPMC, Paris, France.
Pascal PommierCentre Leon Berard, Department of Radiation Oncology, Lyon, France.
Thomas LacornerieCentre Oscar Lambret, Academic Department of Radiation Oncology, University Lille II, Lille, France.
Geoffrey MartinageCentre Oscar Lambret, Academic Department of Radiation Oncology, University Lille II, Lille, France.
Emmanuelle TreschDepartment of biostatistics, Centre Oscar Lambret, Lille, France.
Eric LartigauCentre Oscar Lambret, Academic Department of Radiation Oncology, University Lille II, Lille, France.
Centre Oscar Lambret · FRCentre National de la Recherche Scientifique · FRCentre Léon Bérard · FRInstitut de Cancérologie de Lorraine · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDose escalation may improve curability in intermediate-risk prostate carcinoma. A multicenter national program was developed to assess toxicity and tumor response with hypofractionated stereotactic boost after conventional radiotherapy in intermediate-risk prostate cancer. METHODS AND MATERIAL: Between August 2010 and April 2013, 76 patients with intermediated-risk prostate carcinoma were included in the study. A first course delivered 46 Gy by IMRT (68.4% of patients) or 3D conformal radiotherapy (31.6% of patients). The second course delivered a boost of 18 Gy (3x6Gy) within 10 days. Gastrointestinal (GI) and genitourinary (GU) toxicities were evaluated as defined by NCI-CTCAE (v4.0). Secondary outcome measures were local control, overall and metastasis-free survival, PSA kinetics, and patient functional status (urinary and sexual) according to the IIEF5 and IPSS questionnaires.

resultsThe overall treatment time was 45 days (median, range 40-55). Median follow-up was 26.4 months (range, 13.6-29.9 months). Seventy-seven per cent (n = 58) of patients presented a Gleason score of 7. At 24 months, biological-free survival was 98.7% (95% CI, 92.8-99.9%) and median PSA 0.46 ng/mL (range, 0.06-6.20 ng/mL). Grade ≥2 acute GI and GU toxicities were 13.2% and 23.7%, respectively. Grade ≥2 late GI and GU toxicities were observed in 6.6% and 2.6% of patients, respectively. No grade 4 toxicity was observed.

conclusionsHypofractionated stereotactic boost is effective and safely delivered for intermediate-risk prostate carcinoma after conventional radiation. Mild-term relapse-free survival and tolerance results are promising, and further follow-up is warranted to confirm the results at long term.

trial registrationClinicalTrials.gov NCT01596816.

Indexed as

AgedAged, 80 and overHumansMaleMiddle AgedProstatic NeoplasmsRadiotherapy, Intensity-Modulated

Identifiers

PMID29190707
PMCPMC5708754
OpenAlexW2774168605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.